Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Ipatasertib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Fallopian Tube Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Skin Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Pancreatic Acinar Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Adenoid Cystic Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Adrenal Gland Pheochromocytoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Neuroendocrine Tumor Of The Anal Canal	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Anal Canal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Anal Canal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Angiosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Apocrine Sweat Gland Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Mucinous Adenocarcinoma Of The Appendix	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Astrocytoma, IDH-Mutant, Grade 4	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Bartholin Gland Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Basal Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Bladder Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Bladder Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Bladder Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Metaplastic Breast Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Cervical Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Chordoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Colorectal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Desmoid Tumor	National Cancer Institute (NCI)	P2	CCC (53)

Showing 1476 to 1500 of 3,272 assets

PreviousPage 60 of 131Next